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Abstract
Background: Fleas are a common ectoparasite of domestic cats and there is a need for novel treatments that
improve feline flea control.
Methods: This investigator-blinded, multi-center randomized, positive-controlled study evaluated the flea control in
cats provided by a single owner-applied treatment with a fluralaner topical formulation compared with a positive
control. Households with up to five healthy cats, all at least 12 weeks of age and weighing at least 1.2 kg (2.6 lb),
were randomized in an approximate 3:1 ratio of fluralaner to positive control. All cats in households randomized to
the positive control group were dispensed three treatments, at 4-week intervals, of a commercial formulation of
fipronil/(S)-methoprene. All cats in households randomized to the fluralaner group were dispensed an initial
treatment at enrollment and a second treatment at week 12 for an additional 3-week observation of treatment
safety. One primary cat with at least five live fleas at enrollment was randomly selected within each household. Flea
counts were performed on all primary cats at 4-week intervals through week 12. Efficacy measurement was based
on reduction in flea counts from baseline. Treatment was considered effective at weeks 4, 8 and 12 if mean live flea
count reductions were 90% or greater and statistically significantly different (P ≤ 0.05) from counts at enrollment.
Results: In 18 investigational veterinary clinics across 11 USA states, 116 households (224 cats) were randomized to
receive topical fluralaner and 45 households (87 cats) were randomized to the fipronil-methoprene combination.
Fluralaner was demonstrated to be effective at 4 weeks (99.1% flea count reduction), 8 weeks (99.5%), and 12 weeks
(99.0%), and all reductions were significantly different from the enrollment count (all P < 0.0001). The fipronil-
methoprene combination was < 90% effective at each post-treatment assessment, with peak efficacy of 75.4% at
12 weeks (all P < 0.0001). No treatment-related serious adverse events were reported in either group.
Conclusions: Owner-applied fluralaner topical treatment was safe in cats and was highly effective in killing fleas
over the subsequent 12 weeks.
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Background
Infestation of cats with the flea Ctenocephalides felis can
be a cause of irritation, leading to pruritus, erythema,
excoriations arising from self-mutilation through
scratching, and development of papules to produce the
condition of feline miliary dermatitis [1]. The rapid ac-
cumulation of large-scale flea challenge in any household
can be attributed to several factors: the ability of an
adult female flea to produce as many as 50 eggs per day;
the potentially short flea life-cycle which can be com-
pleted in as little as 12 to 14 days; and optimal condi-
tions of humidity and temperature that favor a short flea
prepatent period [2]. Thus, absence of adherence to an
effective flea control program in cats can quickly lead to
a household flea problem.
Fleas have been incriminated as the main vector of cat
to human transmission of Bartonella species, including
Bartonella felis, the causative agent of cat scratch disease
[3]. Fleas have also been shown to be carriers of other
potentially zoonotic organisms, including Rickettsia felis
and Rickettsia typhi, and the cestode Dipylidium cani-
num. This tapeworm requires rigorous flea treatment for
control, rather than reliance solely on direct cestodicidal
chemotherapy [3–5]. Effective flea control is therefore
important to reduce the challenge this parasite presents
to household pets and their human cohabitants.
The isoxazolines represent a novel family of antipara-
sitics that provide safe and effective tick and flea protec-
tion for dogs. Fluralaner (Bravecto®; Merck Animal
Health) is the only isoxazoline that provides 12 weeks of
immediate and persistent flea and tick efficacy for dogs
[6–9]. Field studies in the USA, Europe and Australia
demonstrated the safety and efficacy of orally adminis-
tered fluralaner for reducing flea and tick infestations on
dogs [10–12]. A recent study showed that under field
conditions, a topical fluralaner formulation provides a
level of flea control in dogs that aligns with that pro-
vided by the oral product [13].
To date, no isoxazoline has been shown to be safe and
effective for cats. Fluralaner topical solution has favor-
able pharmacokinetics in cats and can provide an easily
administered option for flea and tick control on cats
[14]. A field study was therefore designed to assess the
flea control efficacy of topical fluralaner dispensed to cat
owners for at-home administration in the USA.
The primary objective of this positive-controlled, ran-
domized, single-blinded study was to investigate the clin-
ical safety and efficacy of topical fluralaner to treat and
control natural flea infestations for at least 12 weeks
(84 days). The results were compared to a group treated
with a positive control at 4-week intervals and followed
for 12 weeks (84 days) using a commercial formulation of
fipronil/(S)-methoprene (Frontline® Plus for Cats; Merial).
Following the 12 week efficacy evaluation, cats treated
with fipronil-methoprene combination were off the study;
cats assigned to topical fluralaner were administered a sec-
ond dose of fluralaner and followed for 3 more weeks
(through Day 105, week 15) for safety observations.
Methods
The study protocol, finalized in early 2013, used then-
current guidelines for evaluating flea and tick parasiti-
cides [15]. It also complied with Good Clinical Practice
(VICH GL9) and the International Guiding Principles
for Biomedical Research Involving Animals. Written in-
formed consent was obtained from each owner for all
household cats prior to the commencement of any
screening activities. Enrollment eligibility included
households that had no more than five cats, all of which
were at least 12 weeks of age, weighed at least 1.2 kg
(2.6 lb), and were in generally good health as determined
by a veterinary examination prior to enrollment; and at
least one cat in the household had a minimum of five
live fleas counted prior to enrollment. There were no
breed or gender restrictions, but households with preg-
nant or lactating cats were not eligible for enrollment.
Households in which the cats had exposure to non-
confined pets, other than cats, that could harbor fleas
(e.g. dogs) were not eligible. There were also restrictions
on the pre-enrollment/historical use of any approved (in
the USA, as this was a USA study) flea control medica-
tions or products, based on the approved label duration.
Products labeled for 12-week use had a minimum 84-
day washout, products labeled for monthly use had a
minimum 30-day washout, products labeled for use
every 2 weeks had a minimum 14-day washout, and
products labeled for weekly use had a 7-day washout.
At each of the 18 participating investigational veterin-
ary clinics, enrolled households were randomly assigned
between two treatment groups in a 3:1 (fluralaner topi-
cal:fipronil-methoprene combination) ratio. No single
clinic was permitted to contribute more than 40% of the
households that participated in the study in either treat-
ment group. The treatment groups were:
1. Fluralaner topical solution for cats was dispensed for
owner administration on Day 0. The efficacy
assessment phase of the study lasted for 12 weeks. A
second fluralaner topical solution dose was
dispensed 12 weeks after the first for additional
safety assessment. At least 100 households were
targeted for assignment to the topical fluralaner
group. Topical fluralaner was provided as a 28% w/v
solution in single-dose applicators in three sizes,
containing either 112.5 mg, 250 mg or 500 mg of
fluralaner, in volumes of 0.4, 0.89 and 1.79, respect-
ively, with dosing weight bands established to
achieve a minimum dose of 40 mg/kg.
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2. Fipronil/(S)-methoprene spot-on solution (Frontline®
Plus for Cats; Merial Limited, Duluth, GA), was dis-
pensed for application once every 28 days for three
doses. A minimum of 33 households were targeted
for enrollment into this group. The fipronil-
methoprene combination (containing 9.8% fipronil
and 11.8% (S)-methoprene) remained in its commer-
cial packaging containing a volume of 0.5 ml.
At each site, households were assigned to treatment
according to a randomized complete block design, with
order of entry into the study as the blocking factor and
assignment of cats to treatment within blocks in a ratio
of 3:1 of fluralaner-treated to fipronil-methoprene-
treated. A primary cat from each household was ran-
domly selected from cats with at least five live fleas. Sep-
arate randomization tables were provided to each site
for assignment of households to treatment group and se-
lection of the primary cat. All cats within an enrolled
household were assigned to the same treatment group.
Each clinic had at least one dispensing administrator
who had access to randomization tables and was respon-
sible for dispensing all treatments to owners. Adminis-
trators did not participate in the collection or recording
of flea count data or the assessment of flea allergy
dermatitis (FAD). Study personnel who participated in
the collection or recording of flea count data or the as-
sessment of FAD through the final visit were blinded to
treatment assignment.
All treatments were administered at home by cat
owners, who were not blinded. For households random-
ized to the fluralaner group, owners were provided in-
structions on application, including parting the hair and
placing the tip on the skin at the base of the skull and
squeezing out the contents onto one or more spots in
amounts that would limit risk of run-off from any one
spot. After administration, the owner was instructed to
observe the cat to determine if any of the solution ran
or dripped off the animal during or immediately follow-
ing treatment. Owners of cats randomized to the
fipronil-methoprene group were instructed to dose ac-
cording to label directions.
Enrollments were completed during the first clinic
visit, during which treatments were dispensed and blood
and urine samples collected for baseline clinical path-
ology data. Owners were required to bring their cats into
the clinic for recheck visits approximately 4, 8, and
12 weeks after enrollment (on Days 28 [± 2], 56 [± 3],
and 84 [± 3]). Blood and urine samples were collected
for clinical pathology data for all cats at week 12. House-
holds assigned to fipronil-methoprene were off study
after the week 12 visit. For households randomized to
the fluralaner group, cats were also rechecked for assess-
ments of safety (including a 3rd blood and urine sample
collection for clinical pathology) and signs of FAD on
week 15 (Day 105 [± 3], 3 weeks after the second flurala-
ner treatment).
From enrollment until week 12 (Day 84) of the study,
owners were asked to avoid any premises treatments for
environmental flea control, either in their house or on
their property. No concomitant treatments for flea and/
or tick infestations were permitted, and the investigator
or designee was asked to observe an adequate washout
period (consistent with any USA-approved labeling) for
any such treatments received prior to enrollment. Con-
comitant treatments for disorders other than flea and
tick infestations were permitted, if they were not ex-
pected to interfere with assessments of flea and tick in-
festations. For example, treatments for prevention and
control of internal parasite infestations (including heart-
worm and gastrointestinal parasites) were permitted, if
any product used was not labeled for flea or tick control.
Treatment that could affect assessment of signs of FAD
(for example steroids, antihistamines, creams, ointments,
baths, etc.) was permissible. However, data from any
such treated cat were subsequently excluded from the
analysis of FAD clinical signs. Grooming, bathing, swim-
ming, and other water activities were permitted during
the study, with some exceptions. To avoid any effect on
recovery of fleas and ticks, grooming and bathing were
disallowed within 72 h before any scheduled recheck
visit through week 12 (Day 84). In addition, bathing,
swimming, and other water activities were not allowed
for 72 h after application of any study treatment.
Owners were instructed to observe their cats for any
adverse events and to document such observations in a
study-provided diary and to report them as soon as they
occurred or at the next scheduled visit. Flea counting
was conducted in clinics by blinded personnel, using a
flea comb to perform a full-body flea count for at least
10 min; live fleas were counted, removed, and placed in
a soap solution. After this 10 min period the flea counter
was permitted to stop when they were confident that all
fleas had been recovered.
Examinations at each visit included a veterinarian’s as-
sessment of the presence of six signs of FAD (erythema,
alopecia, papules, scales, crusts, and excoriations) and
their severity (mild, moderate, severe). Pruritus observa-
tions were recorded by owners and reported.
The primary efficacy endpoint was based on reduction
in mean flea counts compared to baseline, with house-
hold as the experimental unit, represented by one pri-
mary cat.
Efficacy assessment
Arithmetic and geometric mean live flea counts were
calculated separately for each treatment group at each
assessment and the percentage reduction at each time
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point was based on a comparison to baseline according
to the formula:




where D0 =mean live flea count at baseline of primary
cats; and Dx =mean live flea count on Day x (x = 28
[4 weeks], 56 [8 weeks] or 84 [12 weeks]) of primary
cats.
Both geometric means and arithmetic means were
compared using the live flea counts and log-transformed
live flea counts (log[live flea count + 1]) for each house-
hold (represented by one primary cat). A mixed linear
model with repeated measures was used for the analysis.
The model included treatment, visit and treatment*visit
as fixed effects, site as a random effect and household as
the subject with repeated measures. A Kenward-Rogers
adjustment was used to determine the denominator de-
grees of freedom for hypothesis testing. Akaike’s Infor-
mation Criterion (AIC) was used as the criterion to
select the covariance structure for repeated measures.
Least squares means were used for comparisons and for
the log-transformed data, the least squares means were
back transformed to obtain the estimates of geometric
mean live flea counts. Within each treatment group, the
live flea counts at each post-treatment visit (Day 28, 56
and 84) were compared with that at the baseline (Visit
1). At each visit, live flea counts were compared between
the two treatment groups. Two-sided t-tests at a 5%
level of significance were used for all pairwise compari-
sons. SAS version 9.3 was the primary software used for
analysis. Treatment was considered effective at a given
time point if the mean (geometric or arithmetic) live flea
count reduction was 90% or greater and significantly dif-
ferent (P ≤ 0.05) from baseline [15].
Numbers and percentages of primary cats that showed
at least 90% reduction in flea burden, as well as the
numbers and percentages of primary cats with zero fleas
counted in each treatment group at each visit were cal-
culated. A non-parametric asymptotic approach was
used to test the differences of the percentages between
treatment groups. The non-parametric analyses were
performed using StatXact version 9. The study was only
designed to perform statistical comparisons of the flea
counts. Signs of FAD and AEs were only examined de-
scriptively. Thus, no P-values were presented for these
outcomes.
Results
Between May and December 2013, 311 cats from 161
households were enrolled at 18 sites across 11 states:
Alabama (one site), Florida (two sites), Illinois (two
sites), Maine (one site), Louisiana (two sites), Missouri
(one site), New Jersey (one site), Pennsylvania (three
sites), Rhode Island (one site), Tennessee (one site), and
Texas (three sites). There were 116 households (i.e. 116
primary cats) with a total of 224 cats randomized to the
topical fluralaner group (43.1% were single-cat house-
holds), and 45 households with a total of 87 cats ran-
domized to the fipronil-methoprene combination group
(40.0% single-cat households). Gender distribution, age
ranges, and body weights were generally similar between
the groups (Table 1). The youngest cats enrolled in the
study were 12 weeks of age in the fluralaner group and
13 weeks of age in the fipronil-methoprene group; 10.7%
of fluralaner cats and 11.5% of fipronil-methoprene cats
were less than 26 weeks. Several breeds were enrolled,
but the most common breeds were domestic shorthair
cats (64.7% of fluralaner cats and 75.9% of fipronil-
methoprene cats), domestic long hair cats (15.2 and
3.4%), domestic medium hair cats (6.7 and 2.3%), and
Siamese pure and crossbreeds (2.7 and 9.2%). Other
breeds observed in lower frequencies (less than 5% of ei-
ther treatment group) included pure and crossbreeds
Siamese, Ragdoll, Himalayan, Persian, Manx, Bengal,
Maine Coon, and Turkish Angora.
In both treatment groups, primary cats occasionally
missed visits during this field study, and therefore did
not have flea count data generated. In the fluralaner
group, there were there were eight primary cats that
missed at 8 weeks and nine primary cats that missed at
12 weeks. In the fipronil-methoprene combination
group, there were four primary cats that missed at
4 weeks, six primary cats that missed at 8 weeks, and
nine primary cats that missed at 12 weeks. In addition,
flea count data were collected, but excluded from flea ef-
ficacy calculations in both groups for reasons including
inaccurate dosing, bathing prior to flea count, insecti-
cidal treatment of the household, and/or administration
of other insecticides to the cat. In the fluralaner group,
flea count data were excluded from two primary cats at
4 weeks, from two primary cats at 8 weeks, and from
two primary cats at 12 weeks. In the fipronil-
methoprene combination group, flea count data were ex-
cluded from one primary cat at 4 weeks, from one pri-
mary cat at 8 weeks, and from two primary cats at
12 weeks.
In the fluralaner group, reductions in geometric mean
counts at 4 weeks (99.1%), 8 weeks (99.5%), and 12 weeks
(99.0%) were all statistically significantly different from
baseline (all P < 0.0001) (Table 2). Arithmetic mean flea
count reductions in the fluralaner group were 98.6, 99.1
and 98.7% on weeks 4, 8 and 12, respectively (Table 2,
Fig. 1, all P < 0.0001). The percentages of individual
fluralaner-treated primary cats with a ≥ 90% reduction in
flea burden from baseline were 93.9% at 4 weeks, 96.2%
at 8 weeks, and 93.3% at 12 weeks. The percentages of
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individual fluralaner-treated primary cats with 0 fleas de-
tected (i.e. a 100% reduction) were 80.7% at 4 weeks,
88.7% at 8 weeks, and 80.0% at 12 weeks. The maximum
12-week flea count on a primary cat in the fluralaner
group was 11 fleas. This was the only one of 105
fluralaner-treated primary cats with a 12-week burden of
10 or more fleas.
At each post-treatment assessment of the fipronil-
methoprene combination group, geometric mean flea
count reductions from baseline were significant (all
P ≤ 0.0001), but at no point did they reach 90%
(46.5% at 4 weeks, 66.6% at 8 weeks, and 75.8% at
12 weeks). Similarly, arithmetic mean flea count re-
ductions from baseline were significant (P ≤ 0.0006),
but at no point did they reach 90% (55.2% at 4 weeks,
65.5% at 8 weeks, and 75.4% at 12 weeks). The per-
centages of individual fipronil-methoprene-treated pri-
mary cats with a ≥ 90% reduction in flea burden from
baseline were 10.0% at 4 weeks, 31.6% at 8 weeks,
and 38.2% at 12 weeks. The percentages of individual
fipronil-methoprene-treated primary cats with 0 fleas
detected (i.e. a 100% reduction) were 5.0% at 4 weeks,
21.1% at 8 weeks, and 23.5% at 12 weeks. In six
fipronil-methoprene combination product-treated
households, the counts at 12 weeks were higher than
at enrollment, and at least one clinic in each of Ala-
bama, Illinois, Louisiana, Maine, and Missouri
identified a primary fipronil-methoprene-treated cat
with at least 20 fleas-single cat households repre-
sented 70% of the primary cats with at least 20 fleas
at 12 weeks.
In both groups, there was improvement in all signs of
flea allergy dermatitis (Table 3). The most common
manifestation of FAD observed in study cats was alope-
cia, which at enrollment was recorded for 60 of 224
(26.8%) cats in the fluralaner group and 18 of 84 (21.4%)
cats in the fipronil-methoprene combination group. At
12 weeks, the percentage of eligible cats in which this
sign was seen to have resolved was 84.4% in the flurala-
ner and 50.0% in the fipronil-methoprene combination
group.
Across the 12 weeks of the study in all cats of both
treatment groups and for an additional 3 weeks follow-
ing the second treatment of fluralaner-treated cats, there
were no serious adverse events. All adverse events were
unremarkable throughout the study. A review of study
records and owner diaries showed the most common ad-
verse event in each group to be vomiting, affecting 7.6%
of fluralaner-treated cats and 6.9% of fipronil-
methoprene-treated cats. Other adverse events occurred
at generally similar rates in both groups, although prur-
itus was reported in 11.5% of fipronil-methoprene-
treated cats and 5.4% of fluralaner-treated cats; diarrhea
and decreased appetite were reported in more
fluralaner-treated cats (4.9 and 3.6%, respectively) than
fipronil-methoprene-treated cats (1.1 and 0.0%, respect-
ively) (Table 4).
Both groups underwent a detailed blood count and
blood and urine analysis and the results were unremark-
able, with no evidence suggesting a pathologic trend,
and only occasional isolated departures from normal ref-
erence ranges in blood and urine analyses. There were
no clinically relevant differences between the results of
the two groups.
Discussion
This 12-week field study found that a single topical
administration of fluralaner provided a greater than
99% (by geometric mean; ≥ 98.6% by arithmetic
mean) flea control efficacy over 12 weeks. Under
equivalent field challenge conditions, flea control effi-
cacy never exceeded 90% in the positive control
group treated three times with a fipronil/(S)-metho-
prene combination. The results of this field study in
cats align with the results of three similarly designed
studies in dogs - two investigating the chewable flura-
laner formulation, and one investigating the use of
the same topical formulation used in this study [10,
11, 13]. In all of the dog fluralaner field studies, a
single treatment/application has resulted in a > 99%
reduction in geometric mean live flea counts within
Table 1 Demographics of enrolled cats and distribution of













Mean (SD) 9.7 (3.20) 10.2 (3.86)
Range 2.6–16.9 2.6–25.3
Gender Female, Intact 27 (12.1%) 7 (8.0%)
Female,
Spayed
93 (41.5%) 35 (40.2%)
Male, Intact 15 (6.7%) 13 (14.9%)




1 50 (43.1%) 18 (40.0%)
2 40 (34.5%) 21 (46.7%)
3 15 (12.9%) 1 (2.2%)
4 6 (5.2%) 1 (2.2%)
5 5 (4.3%) 4 (8.9%)
aIn the fluralaner group, the youngest cats enrolled were 12 weeks of age; 24
(24/224 = 10.7%) were less than 26 weeks of age
bIn the fipronil-methoprene group, the youngest cats enrolled were 13 weeks
of age; 10 (10/87 = 11.5%) were less than 26 weeks of age
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one month, and sustained flea count reductions of >
99% through 12 weeks post-treatment.
Both fluralaner and fipronil-methoprene combination
products were well tolerated in this study. There were
no detectable effects of either product on clinical
pathology tests (baseline and week 12 for fipronil-
methoprene cats; baseline, week 12, and week 15 for
fluralaner cats).
There are few published reports of clinical field studies
that focus on flea control measures in cats, with only
Table 2 Flea count data for primary cats in the fluralaner topical and fipronil/(S)-methoprene groups. No efficacy comparison was




(Week 4, Day 28)
Visit 3
(Week 8, Day 56)
Visit 4
(Week 12, Day 84)
Number of primary cats
Fluralaner topical solution 116 114 106 105
Fipronil/(S)-methoprene
spot-on solution
45 40 38 34
Arithmetic mean flea
count (95% CI)
Fluralaner topical solution 47.8 (36.5–59.1) 0.7 (0.1–1.3) 0.4 (0.0–1.0) 0.6 (0.3–0.9)
Fipronil/(S)-methoprene
spot-on solution
83.0 (24.7–141.2) 37.1 (14.5–59.7) 28.6 (14.3–42.9) 20.4 (10.0–30.8)
P-value for comparisona t(158.9) = -1.71, P = 0.0899 t(160.5) = -5.17, P < 0.0001 t(155.8) = -6.35, P < 0.0001 t(148.4) = -6.88, P < 0.0001
% efficacy (reduction from baseline)
based on arithmetic means
Fluralaner topical solution na 98.6 99.1 98.7
P-value for comparison to baselinea na t(158.5) = 5.51, P < 0.0001 t(159.2) = 4.74, P < 0.0001 t(159.1) = 4.50, P < 0.0001
Fipronil/(S)-methoprene
spot-on solution
na 55.2 65.5 75.4
P-value for comparison to baselinea na t(160.4) = 3.49, P = 0.0006 t(159.9) = 3.50, P = 0.0006 t(159.6) = 3.75, P = 0.0002
Geometric mean flea count (95% CI)
Fluralaner topical solution 28.0 (23.2–33.8) 0.2 (0.1–0.4) 0.1 (0.0–0.2) 0.3 (0.2–0.4)
Fipronil/(S)-methoprene
spot-on solution
28.0 (19.2–40.9) 15.0 (9.5–23.3) 9.4 (5.2–16.4) 6.8 (3.6–12.1)
P-value for comparisona t(139.9) = 0.07, P = 0.9474 t(139.7) = -17.56, P < 0.0001 t(144.7) = -13.23, P < 0.0001 t(139.3) = -10.80, P < 0.0001
% efficacy (reduction from baseline)
based on geometric means
Fluralaner topical solution na 99.1 99.5 99.0
P-value for comparison to baselinea na t(151.9) = 32.41, P < 0.0001 t(150.8) = 30.60, P < 0.0001 t(147.1) = 29.81, P < 0.0001
Fipronil/(S)-methoprene spot-on solution na 46.5 66.6 75.8
P-value for comparison to baselinea na t(159.3) = 3.96, P = 0.0001 t(155.9) = 6.11, P < 0.0001 t(158.4) = 7.68, P < 0.0001
% of primary cats with at least 90%
reduction from baseline flea count
Fluralaner topical solution na 93.9 96.2 93.3
Fipronil/(S)-methoprene
spot-on solution
na 10.0 31.6 38.2
P-value for comparisonb na Z = -10.17, P < 0.0001 Z = -7.26, P < 0.0001 Z = -6.96, P < 0.0001
% of flea-free primary cats
Fluralaner topical solution na 80.7 88.7 80.0
Fipronil/(S)-methoprene
spot-on solution
na 5.0 21.1 23.5
P-value for comparisonb na Z = -8.45, P < 0.0001 Z = -7.87, P < 0.0001 Z = -6.05, P < 0.0001
Abbreviation: na value or calculation is not applicable
aP-value for comparison of model least squares means parameter estimates
bP-value for comparison of percentages using non-parametric asymptotic approach and Standardized Statistic
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one in which enrollments were from cat-only (i.e. no
dogs) households [16]. In that study, cats received
two sequential monthly treatments with orally admin-
istered spinosad or topically applied selamectin. At
the final assessment 30 days after the second treat-
ment (Day 60), arithmetic mean flea count reductions
from pre-treatment levels were 98.7 and 98.2% in the
spinosad and selamectin groups, respectively, with
91.0 and 87.9% of cats in each group free of fleas.
Those efficacy findings align with observations for
fluralaner single-treatment efficacy at 8 weeks in this
study, although the fipronil-methoprene group efficacy
results reported here appear to lag behind other
treatments.
The flea control efficacy observed in this study follow-
ing treatment with a fipronil-methoprene combination
product was inconsistent. Six primary cats treated with
fipronil-methoprene combination had flea counts that
were higher at 12 weeks than at enrollment; five owners
withdrew from the study prior to 12 weeks because of
perceived inefficacy; and, 23.5% of primary cats were flea
free while 38.2% had a 90% or greater reduction in flea



























































Fig. 1 Arithmetic mean flea counts and percent reduction from baseline
to weeks 4, 8 and 12 for topical fluralaner or fipronil/(S)-methoprene-
treated cats (bars indicate arithmetic flea counts; lines indicate percentage
reductions from baseline)
Table 3 Summary of alleviation in each sign of flea allergy dermatitis in cats
Sign Fluralaner topical solution Fipronil/(S)-methoprene spot-on solution
Erythema Number of cats with sign at initial exam that
were also eligible for
re-examination at 12 weeks
26 6
% of cats with lesion resolved at 12-week
re-examination
80.8 33.3
Alopecia Number of cats with sign at initial exam that
were also eligible for
re-examination at 12 weeks
45 12
% of cats with lesion resolved at 12-week
re-examination
84.4 50.0
Papules Number of cats with sign at initial exam
that were also eligible for
re-examination at 12 weeks
6 1
% of cats with lesion resolved at 12-week
re-examination
100.0 100.0
Scales Number of cats with sign at initial exam
that were also eligible for
re-examination at 12 weeks
15 2
% of cats with lesion resolved at 12-week
re-examination
100.0 100.0
Crusts Number of cats with sign at initial exam
that were also eligible for
re-examination at 12 weeks
24 7
% of cats with lesion resolved at 12-week
re-examination
95.8 57.1
Excoriation Number of cats with sign at initial exam
that were also eligible for
re-examination at 12 weeks
25 4
% of cats with lesion resolved at
12-week re–examination
100.0 75.0
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previous reports describing inadequate fipronil flea con-
trol efficacy [13, 17, 18], and to the potential need for
further investigation into explanations for this weaker
than expected performance.
FAD clinical signs resolved in most fluralaner-
treated cats, an observation that is consistent with
results following fluralaner treatment of FAD af-
fected dogs. In this field study the diagnosis of FAD
was based exclusively on clinical signs and it is pos-
sible that some of the clinical signs observed at en-
rollment were not caused by flea bites. Studies
using more detailed diagnostic methods in dogs
have observed a greater response following effective
flea treatment [12, 19].
Conclusions
In conclusion, a single topical administration of flurala-
ner to cats is well tolerated and highly effective in con-
trolling flea infestations on cats for 12 weeks following
administration under typical household conditions.
Abbreviation
FAD: Flea allergy dermatitis
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